What Fueled The Previous Growth In The Viral Vectors And Plasmid DNA Manufacturing Market?
The viral vectors and plasmid dna manufacturing market has seen considerable growth due to a variety of factors.
• In recent years, the market size for viral vectors and plasmid dna manufacturing has seen rapid growth. The market is projected to increase from $5.75 billion in 2024 to $7.11 billion in 2025, growing at a compound annual growth rate (CAGR) of 23.8%.
The surge during the historical period can be credited to the rising demand for customised medicine, advancements in vaccine development, availability of funds for gene therapy research, effectiveness of viral vectors in the delivery of gene therapy, and their potential uses in innovative drug delivery methods.
How Does the Forecast Look for the Viral Vectors And Plasmid DNA Manufacturing Market?
The viral vectors and plasmid dna manufacturing market is expected to maintain its strong growth trajectory in upcoming years.
• The market for viral vectors and plasmid DNA manufacturing is anticipated to undergo substantial growth in the forthcoming years, swelling to $16.52 billion by 2029 at a CAGR of 23.5%.
The growth predicted during the forecast period can be accredited to factors such as the growing number of gene therapies, an increasing number of market players, rising prevalence of infectious diseases and genetic disorders, augmented investments in the cell and gene therapy research sector, and a higher incidence of targeted disorders and diseases. Noteworthy trends during the forecast duration encompass technological progress, advancements in gene therapy, the implementation of cutting-edge technologies, the use of single-use technologies, and developments in vaccine technology.
What Are The Leading Drivers Of Growth In The Viral Vectors And Plasmid DNA Manufacturing Market?
The viral vectors and plasmid DNA manufacturing market is being propelled forward by the rising number of gene therapies. These treatments, which involve changing, introducing or removing a person's cellular genetic material, are crucial in treating and preventing diseases. This growth in gene therapy is facilitated by increased investment in biotechnology research and development, in addition to a more comprehensive understanding of the genetic and cellular causes of various diseases. Viral vectors and plasmid DNA manufacturing are pivotal as they deliver therapeutic genes into the cells of patients, allowing treatment of genetic illnesses at a molecular level. As an example, the US-based non-profit medical and scientific organization, the American Society of Gene & Cell Therapy, reported a growth of 10% in gene therapies in Phase III clinical trials in Q3 2023. This was the first quarterly increase since Q3 2022. As such, the viral vectors and plasmid DNA manufacturing market is being driven forward by the increasing number of gene therapies.
How Are The Segments Defined Within The Global Viral Vectors And Plasmid DNA Manufacturing Market?
The viral vectors and plasmid dna manufacturing market covered in this report is segmented –
1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Viral Vector, Non-Viral Vector
2) By Scale Of Operation: Preclinical, Clinical, Commercial
3) By Therapeutic Area: Oncological Disorders, Rare Diseases, Neurological Disorders, Sensory Disorders, Metabolic Disorders, Musculoskeletal Disorders, Blood Disorders, Immunological Disorders, Other Disorders
4) By Application Area: Gene Therapies, Cell Therapies, Vaccines
5) By Type Of Manufacturer: In-house Manufacturers, Contract Manufacturing Organizations
Subsegments:
1) By Plasmid Deoxyribonucleic Acid (DNA): Linear Plasmid DNA, Circular Plasmid DNA, High-Copy Plasmid DNA, Low-Copy Plasmid DNA
2) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, Adeno-Associated Viral Vectors (AAV), Retroviral Vectors
3) By Non-Viral Vector: Liposome-Based Vectors, Polymer-Based Vectors, Nanoparticle-Based Vectors, Electroporation-Based Vectors
Pre-Book The Viral Vectors And Plasmid DNA Manufacturing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Viral Vectors And Plasmid DNA Manufacturing Market?
Leading businesses in the viral vectors and plasmid DNA manufacturing sector are prioritizing strategic collaborations to grow their manufacturing capabilities, improve their technological prowess, and speed up the global development and market initiation of gene therapies. These partnerships allow the sharing of resources and infrastructures, thereby boosting overall production capacity to answer the rising demand for gene therapies. For example, Charles River Laboratories International Inc., a US-based preclinical and clinical contract research organization, and Captain T Cell, a spinoff from the esteemed Max Delbrück Center in Berlin, Germany, kickstarted a plasmid DNA and retrovirus vector production program agreement in June 2024. This partnership gives Captain T Cell entry to affirmed contract development and manufacturing (CDMO) capabilities and consulting services. Furthermore, it seeks to expedite the transition from preclinical studies to clinical trials for a pioneering TCR-T cell therapy targeting solid tumors.
Who Are the Key Players In The Viral Vectors And Plasmid DNA Manufacturing Market?
Major companies operating in the viral vectors and plasmid DNA manufacturing market are:
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Astellas Pharma Inc.
• Lonza Group AG
• Catalent Inc.
• Revvity Inc.
• Wuxi Biologics Inc.
• BioMarin Pharmaceutical
• FUJIFILM Diosynth Biotechnologies
• Miltenyi Biotec GmbH
• Aldevron LLC
• Takara Bio Inc.
• Poseida Therapeutics Inc.
• RegenxBio Inc.
• Cobra Biologics
• Finvector Vision Therapies Limited
• Batavia Biosciences B.V.
• uniQure N.V.
• Addgene Inc.
• BioNTech IMFS GmbH
• Creative Biogene Inc.
• Genezen Laboratories Inc.
• Virovek Incorporation
• Waisman Biomanufacturing
• Axplora GmbH
What Is The Most Dominant Region In The Viral Vectors And Plasmid DNA Manufacturing Market?
North America was the largest region in the viral vectors and plasmid DNA manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vectors and plasmid DNA manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
